Interstitial lung disease (ILD) is a broad group of conditions that cause scarring and inflammation in the interstitium, the delicate tissue between the air sacs of the lungs. This scarring stiffens the lungs and makes it harder for oxygen to pass into the blood, leading to breathlessness and a dry cough. Asbestosis is one form of interstitial lung disease, caused specifically by inhaled asbestos fibers.
Origin
The term describes disease of the lung's interstitium, from the Latin interstitium meaning "a space between." It became a clinical grouping as physicians recognized that many different causes could produce similar scarring patterns.
Significance in Asbestos Context
For someone with an asbestos history, interstitial lung disease matters because asbestosis, the scarring caused by asbestos, falls within this group and can look similar to ILD from other causes on scans. Distinguishing asbestos-related scarring from other interstitial diseases, such as idiopathic pulmonary fibrosis, affects both treatment and any legal claim. Signs like pleural plaques, a known asbestos exposure history, and asbestos bodies in tissue help point to asbestosis specifically. Getting the cause right matters, since it shapes prognosis and eligibility for compensation.
Example Sentence
The pulmonologist noted interstitial lung disease on the CT scan, and the pattern along with pleural plaques and his insulation work pointed to asbestosis.
Related Terms
Asbestosis, Pulmonary Fibrosis, Pleural Plaques, Idiopathic Pulmonary Fibrosis, High-Resolution CT, Restrictive Lung Disease
Notes
- Ask whether your scarring pattern and history point specifically to asbestosis rather than another cause of ILD.
- A high-resolution CT scan and a detailed occupational history help distinguish asbestos-related disease from other ILDs.
- Preserve imaging and any pathology; the specific cause affects both treatment and a possible claim.
In the research library
140 studies in our medical research library mention Interstitial Lung Disease in the title or abstract. Among the most cited:
- Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJ. Behr, A. Prasse, M. Kreuter, et al, 2021 · The Lancet. Respiratory Medicine · cited 419 times
- Characterization of the lower respiratory tract inflammation of nonsmoking individuals with interstitial lung disease associated with chronic inhalation of inorganic dustsW.N. Rom, P.B. Bitterman, S.I. Rennard, et al, 1987 · The American Review of Respiratory Disease · cited 214 times
- The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trialL.M. Dowman, C.F. McDonald, C.J. Hill, et al, 2017 · Thorax · cited 211 times
- High-resolution CT-derived measures of lung density are valid indexes of interstitial lung diseaseP.G. Hartley, J.R. Galvin, G.W. Hunninghake, et al, 1994 · Journal of Applied Physiology · cited 125 times
- Exercise alveolar-arterial oxygen pressure difference in interstitial lung diseaseC. Risk, G.R. Epler, E.A. Gaensler, 1984 · Chest · cited 93 times
The journals that publish most on it: The American Review of Respiratory Disease (7), Chest (6), BMJ Open Respiratory Research (5).
Category: Diseases & Conditions · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.